Phispers: IMS Health merges with Quintiles, FDA Compliance Director’s pay package, J&J’s Talcum Powder’s cancer risk

Phispers, our news capsule, brings you the latest recap from the world of pharma, such as up to 20 percent drugs sold in India could be counterfeit, Reckitt Benckiser’s killer disinfectants, after $200 million fine Gilead accuses Merck lawyer of lying, China’s multi-billion pharma opportunity and more.

 

FDA Compliance Director’s pay package pales in comparison with Clinton’s DCAT speaking fee

PharmaCompass noticed a job opening at the US Food and Drug Administrations (FDA) – Director, Office of Compliance. The annual salary for this post mentioned was US $ 123,175 to US $ 185,100.

Now compare this to what Hillary Clinton was paid to speak at DCAT’s Annual Dinner in 2014 – US $ 250,000. Or with Valeant’s new CEO Joseph Papa’s US $ 67 million package which could be worth US $ 500 million if Valeant shares reach their previous record high levels.

The price that the department pays for a post that ‘touches the lives of every American’ certainly seems measly!

 

IMS Health in US $ 9 billion merger deal with Quintiles

In an announcement which caught the market by surprise, industry leaders, contract medical research provider Quintiles Transnational announced a merger with healthcare information company IMS Health Holdings in a deal worth about US $ 9 billion.

The combined company, which will have a market value of nearly US $ 18 billion, will offer services to drug and medical device makers, ranging from helping run clinical trials to tracking sales once a product has hit the market.

The combined company – Quintiles IMS Holdings – will be led by IMS Health chief executive Ari Bousbib. 

 

China’s blood plasma shortage throws opportunities for pharma companies

While China’s blue-chip firms maybe sinking at the bourses, Shanghai RAAS Blood Products, a seller of treatments made from human blood plasma, is rallying new highs. It’s now China’s largest healthcare company by valuation with a market cap of almost US $16 billion (compare that with an IMS & Quintiles combination which is worth $ 18 billion).

The big driver of growth is China’s surging demand for plasma-based therapies. Even though millions in China need these treatments, there’s scarcity of the blood plasma used to make them, partly because Beijing strictly controls the number of companies that have licenses to collect blood.

GSK should definitely look into this opportunity as its sales in China have been tumbling. At the same time Biogen considers hemophilia to be a serious opportunity and plans to spin the division into a separate entity

 

Up to 20 percent drugs sold in India could be counterfeit

In a special report, the office of the US Trade Representative (USTR) has raised major concerns about counterfeit drugs and devices. According to the report, 97 percent of all counterfeit pharmaceuticals seized at the US border in 2015 were shipped from four economies – China, Hong Kong, India and Singapore. Particularly, the USTR has raised concern about the proliferation of counterfeit pharmaceuticals manufactured, sold, and distributed in trading partners such as Brazil, China, Guatemala, India, Indonesia, Lebanon, Peru and Russia. 

While it is impossible to determine an exact figure, studies have suggested that up to 20 percent of drugs sold in the Indian market are counterfeit and could represent a serious threat to patient health and safety.

 

Court orders J&J to pay US $ 55 million to woman who alleged talc caused cancer

In February, J&J was ordered to pay US $ 72 million, in a St. Louis courthouse, to the family of a woman who died of ovarian cancer after having used J&J’s baby powder and another talc-based product for years.

In another loss, Johnson & Johnson needs to pay US $55 million to a 62-year-old South Dakota woman who put the blame for her ovarian cancer on the company’s talcum powder. In the US, J&J is accused in more than 1,000 lawsuits in state and federal courts of ignoring studies linking its Shower-to-Shower product and Johnson’s Baby Powder to ovarian cancer. Women contend the company knew the risk and failed to warn customers. J&J, on the other hand, has denied any link between talc and ovarian cancer or any need to warn women.

 

After US $200 million fine, Gilead accuses Merck lawyer of lying

In March, a federal jury in San Jose ordered Gilead to pay Merck US $200 million after finding that two US patents held by Merck and its partner, Ionis Pharmaceuticals, were valid and infringed by Gilead’s multibillion-dollar hepatitis C drugs – Sovaldi and Harvoni. The patents cover a range of compounds treating hepatitis C. Merck recently began selling its own hepatitis C drug – Zepatier.

After the jury verdict, Gilead argued it shouldn’t have had to pay Merck because Merck was dishonest in obtaining its patents. Gilead said in 2004, Merck patent attorney Philippe Durette had a conference call with employees of Pharmasset, in which he learned the chemical structure of an experimental hepatitis C drug being developed by Pharmasset, code-named PSI-6130. 

Gilead later spent more than US$11 billion to acquire Pharmasset and its hepatitis C drugs. Gilead said Durette misused what he learned on the call to subsequently change claims in pending Merck patent applications in a way that would cover Pharmasset’s technology. 

 

Reckitt Benckiser apologizes for killer disinfectants, even as it misled patients in Australia

Ataur Safdar, head of the Reckitt Benckiser’s Korean division, apologized for selling deadly disinfectants that killed or injured hundreds of people, five years after the government ordered the company to remove the products from shelves for health risks. Safdar said the company wanted to make amends, even as he was interrupted by angry and tearful victims and their family members.

Meanwhile, an Australian court has ordered Reckitt Benckiser to pay 1.7 million Australian dollars in penalties after a ruling that the company misled consumers about the effectiveness of a popular painkiller.

 

Eli Lilly warns of job losses due to ban on carcinogen used to produce raloxifene

Eli Lilly, one of Ireland’s largest pharmaceutical employers, has warned of job losses at its Kinsale plant if the EU does not exempt it from a forthcoming ban on ethylene dichloride (EDC) – a carcinogenic chemical.

Eli Lilly uses the chemical to produce raloxifene, marketed as Evista, a prescription drug to prevent osteoporosis in post-menopausal women. The drug is currently used by 1.7 million patients worldwide.

EDC will be banned within the EU from November 2017.

 

Goggles, hair, insects, dirt in APIs, reveals FDA warning letter to Polydrug Labs

Polydrug Laboratories has been on FDA’s Import Alert List since September 2015. The warning letter issued by the FDA was posted on the regulator’s website and it talks about all kinds of uninvestigated complaints found on a torn sheet of paper recovered during the inspection. 

Amongst these were complaints like low assay value in API and particles and hair, insect and dirt and safety googles found in API. According to the FDA, Polydrug failed to comply with current good manufacturing practices for the manufacture of APIs and also failed to record and investigate all quality-related customer complaints according to an established procedure. More details are available at Barbara Unger’s blog entry.

 

Effort to regulate drug pricing reaches G7 Summit

In March, the French President Francois Hollande had said he would push for international regulation of drug prices when he meets leaders from other G7 countries in Ise-Shima (Japan) on May 26-27. News reports point that the issue is now on the agenda for the G7 Summit and health ministers will continue work on it in Kobe in September when other parties, such as the pharmaceutical companies themselves, could potentially be involved.

France plans to press its G7 partners to launch an ‘irreversible’ process to control the prices of new medicines as part of a global drive to make life-saving drugs more affordable. 

This news has come at a time when the UK too (like the US) is witnessing debates on price gouging, after the price of eye-drops used for bacterial conjunctivitis underwent a 14-fold price increase recently.

 

FDA’s generic drug approval report card 

For the past few weeks, we have been mentioning an acceleration in the review process of generic drug applications filed with the FDA. The FDA recently released its Generic Drug Review Dashboard for the first quarter of 2016.

It wasn’t surprising that the review process has been accelerated as the number of applications pending with the FDA have reduced by almost 10 percent with the burden of work now shifting to the industry which has to respond to the FDA’s comments or concerns. 

 

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : VISIONS: Seeing the Aurora in a New Light by NASA Goddard Space Flight Center is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”